middle.news
FDA Signals Support for Immutep’s Eftilagimod Alfa in Hard-to-Treat Head and Neck Cancer
5:05pm on Thursday 1st of January, 2026 AEDT
•
Healthcare
Read Story
FDA Signals Support for Immutep’s Eftilagimod Alfa in Hard-to-Treat Head and Neck Cancer
5:05pm on Thursday 1st of January, 2026 AEDT
Key Points
FDA endorses further clinical development of eftilagimod alfa with KEYTRUDA for PD-L1 CPS <1 patients
Potential for accelerated approval via Project FrontRunner initiative
Options include randomized registrational trial or smaller single-arm study
Immutep continues Phase III trial focus on non-small cell lung cancer
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE